A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 to December...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Weiping Liu, Donglu Zhao, Ting Liu, Ting Niu, Yongping Song, Wei Xu, Jie Jin, Qingqing Cai, Huiqiang Huang, Zhiming Li, Ming Hou, Huilai Zhang, Jianfeng Zhou, Jianda Hu, Jianzhen Shen, Yuankai Shi, Yu Yang, Liling Zhang, Weili Zhao, Kaiyang Ding, Lugui Qiu, Huo Tan, Zhihui Zhang, Lihong Liu, Jinghua Wang, Bing Xu, Hui Zhou, Guangxun Gao, Hongwei Xue, Ou Bai, Ru Feng, Xiaobing Huang, Haiyan Yang, Xiaojing Yan, Qingshu Zeng, Peng Liu, Wenyu Li, Min Mao, Hang Su, Xin Wang, Jingyan Xu, Daobin Zhou, Hongyu Zhang, Jun Ma, Zhixiang Shen, Jun Zhu
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
lymphoma
T-cell
peripheral
histone deacetylase inhibitors
efficiency
safety
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/5c9000aa953646639a5acb21ddd9d292
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5c9000aa953646639a5acb21ddd9d292
record_format dspace
spelling oai:doaj.org-article:5c9000aa953646639a5acb21ddd9d2922021-11-05T15:04:10ZA Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China2234-943X10.3389/fonc.2021.750323https://doaj.org/article/5c9000aa953646639a5acb21ddd9d2922021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.750323/fullhttps://doaj.org/toc/2234-943XChidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 to December 2017, 548 patients with R/R PTCL from 186 research centers in China were included in the study. Among the 261 patients treated with chidamide monotherapy, ORR was 58.6% and 55 patients (21.1%) achieved complete response (CR). Among the 287 patients receiving chidamide-containing combination therapies, ORR was 73.2% and 73 patients (25.4%) achieved CR. The median OS of all patients was 15.1 months. The median OS of patients receiving chidamide monotherapy and combination therapies was 433 and 463 days, respectively. These results demonstrate a significant survival advantage of chidamide treatments as compared with international historical records. Common adverse effects (AEs) were hematological toxicities. Most AEs in both monotherapy and combined treatments were grade 1–2. No unanticipated AEs occurred. In conclusion, chidamide-based therapy led to a favorable efficacy and survival benefit for R/R PTCL. Future studies should explore the potential advantage of chidamide treatment combined with chemotherapy.Weiping LiuDonglu ZhaoTing LiuTing NiuYongping SongWei XuJie JinQingqing CaiHuiqiang HuangZhiming LiMing HouHuilai ZhangJianfeng ZhouJianda HuJianzhen ShenYuankai ShiYu YangLiling ZhangWeili ZhaoKaiyang DingLugui QiuHuo TanZhihui ZhangLihong LiuJinghua WangBing XuHui ZhouGuangxun GaoHongwei XueOu BaiRu FengXiaobing HuangHaiyan YangXiaojing YanQingshu ZengPeng LiuWenyu LiMin MaoHang SuXin WangJingyan XuDaobin ZhouHongyu ZhangJun MaZhixiang ShenJun ZhuFrontiers Media S.A.articlelymphomaT-cellperipheralhistone deacetylase inhibitorsefficiencysafetyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution DOAJ
collection DOAJ
language EN
topic lymphoma
T-cell
peripheral
histone deacetylase inhibitors
efficiency
safety
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle lymphoma
T-cell
peripheral
histone deacetylase inhibitors
efficiency
safety
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Weiping Liu
Donglu Zhao
Ting Liu
Ting Niu
Yongping Song
Wei Xu
Jie Jin
Qingqing Cai
Huiqiang Huang
Zhiming Li
Ming Hou
Huilai Zhang
Jianfeng Zhou
Jianda Hu
Jianzhen Shen
Yuankai Shi
Yu Yang
Liling Zhang
Weili Zhao
Kaiyang Ding
Lugui Qiu
Huo Tan
Zhihui Zhang
Lihong Liu
Jinghua Wang
Bing Xu
Hui Zhou
Guangxun Gao
Hongwei Xue
Ou Bai
Ru Feng
Xiaobing Huang
Haiyan Yang
Xiaojing Yan
Qingshu Zeng
Peng Liu
Wenyu Li
Min Mao
Hang Su
Xin Wang
Jingyan Xu
Daobin Zhou
Hongyu Zhang
Jun Ma
Zhixiang Shen
Jun Zhu
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
description Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 to December 2017, 548 patients with R/R PTCL from 186 research centers in China were included in the study. Among the 261 patients treated with chidamide monotherapy, ORR was 58.6% and 55 patients (21.1%) achieved complete response (CR). Among the 287 patients receiving chidamide-containing combination therapies, ORR was 73.2% and 73 patients (25.4%) achieved CR. The median OS of all patients was 15.1 months. The median OS of patients receiving chidamide monotherapy and combination therapies was 433 and 463 days, respectively. These results demonstrate a significant survival advantage of chidamide treatments as compared with international historical records. Common adverse effects (AEs) were hematological toxicities. Most AEs in both monotherapy and combined treatments were grade 1–2. No unanticipated AEs occurred. In conclusion, chidamide-based therapy led to a favorable efficacy and survival benefit for R/R PTCL. Future studies should explore the potential advantage of chidamide treatment combined with chemotherapy.
format article
author Weiping Liu
Donglu Zhao
Ting Liu
Ting Niu
Yongping Song
Wei Xu
Jie Jin
Qingqing Cai
Huiqiang Huang
Zhiming Li
Ming Hou
Huilai Zhang
Jianfeng Zhou
Jianda Hu
Jianzhen Shen
Yuankai Shi
Yu Yang
Liling Zhang
Weili Zhao
Kaiyang Ding
Lugui Qiu
Huo Tan
Zhihui Zhang
Lihong Liu
Jinghua Wang
Bing Xu
Hui Zhou
Guangxun Gao
Hongwei Xue
Ou Bai
Ru Feng
Xiaobing Huang
Haiyan Yang
Xiaojing Yan
Qingshu Zeng
Peng Liu
Wenyu Li
Min Mao
Hang Su
Xin Wang
Jingyan Xu
Daobin Zhou
Hongyu Zhang
Jun Ma
Zhixiang Shen
Jun Zhu
author_facet Weiping Liu
Donglu Zhao
Ting Liu
Ting Niu
Yongping Song
Wei Xu
Jie Jin
Qingqing Cai
Huiqiang Huang
Zhiming Li
Ming Hou
Huilai Zhang
Jianfeng Zhou
Jianda Hu
Jianzhen Shen
Yuankai Shi
Yu Yang
Liling Zhang
Weili Zhao
Kaiyang Ding
Lugui Qiu
Huo Tan
Zhihui Zhang
Lihong Liu
Jinghua Wang
Bing Xu
Hui Zhou
Guangxun Gao
Hongwei Xue
Ou Bai
Ru Feng
Xiaobing Huang
Haiyan Yang
Xiaojing Yan
Qingshu Zeng
Peng Liu
Wenyu Li
Min Mao
Hang Su
Xin Wang
Jingyan Xu
Daobin Zhou
Hongyu Zhang
Jun Ma
Zhixiang Shen
Jun Zhu
author_sort Weiping Liu
title A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
title_short A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
title_full A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
title_fullStr A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
title_full_unstemmed A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
title_sort multi-center, real-world study of chidamide for patients with relapsed or refractory peripheral t-cell lymphomas in china
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/5c9000aa953646639a5acb21ddd9d292
work_keys_str_mv AT weipingliu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT dongluzhao amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT tingliu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT tingniu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT yongpingsong amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT weixu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT jiejin amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT qingqingcai amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT huiqianghuang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT zhimingli amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT minghou amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT huilaizhang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT jianfengzhou amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT jiandahu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT jianzhenshen amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT yuankaishi amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT yuyang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT lilingzhang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT weilizhao amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT kaiyangding amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT luguiqiu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT huotan amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT zhihuizhang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT lihongliu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT jinghuawang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT bingxu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT huizhou amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT guangxungao amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT hongweixue amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT oubai amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT rufeng amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT xiaobinghuang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT haiyanyang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT xiaojingyan amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT qingshuzeng amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT pengliu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT wenyuli amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT minmao amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT hangsu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT xinwang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT jingyanxu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT daobinzhou amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT hongyuzhang amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT junma amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT zhixiangshen amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT junzhu amulticenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT weipingliu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT dongluzhao multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT tingliu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT tingniu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT yongpingsong multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT weixu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT jiejin multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT qingqingcai multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT huiqianghuang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT zhimingli multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT minghou multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT huilaizhang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT jianfengzhou multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT jiandahu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT jianzhenshen multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT yuankaishi multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT yuyang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT lilingzhang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT weilizhao multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT kaiyangding multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT luguiqiu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT huotan multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT zhihuizhang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT lihongliu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT jinghuawang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT bingxu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT huizhou multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT guangxungao multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT hongweixue multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT oubai multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT rufeng multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT xiaobinghuang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT haiyanyang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT xiaojingyan multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT qingshuzeng multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT pengliu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT wenyuli multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT minmao multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT hangsu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT xinwang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT jingyanxu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT daobinzhou multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT hongyuzhang multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT junma multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT zhixiangshen multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
AT junzhu multicenterrealworldstudyofchidamideforpatientswithrelapsedorrefractoryperipheraltcelllymphomasinchina
_version_ 1718444163657105408

Ejemplares similares